In a nutshell This study compared the treatment of stable ischemic heart disease (SIHD) with percutaneous coronary angioplasty (PCI) or with medication alone. It found that the risk of mortality was the same in both groups. Some background Coronary artery disease (CAD) is when the blood vessels in the heart become blocked and the heart muscle...Read More
Treatment Posts on Medivizor
In a nutshell This study looked at the ertugliflozin (Steglatro) for patients with type 2 diabetes (T2D) and heart disease. It found that ertugliflozin improved both blood glucose control, body weight, and blood pressure. Some background T2D is a condition in which the levels of glucose (sugar) in the blood are too high. T2D is related to...Read More
Is daratumumab plus RVd a good treatment for patients with newly diagnosed multiple myeloma in the long-term?
In a nutshell The aim of this study was to evaluate the long-term safety and effectiveness of adding daratumumab (Darzalex) to RVd (lenalidomide/bortezomib/dexamethasone) therapy, followed by D-R (daratumumab/lenalidomide) maintenance for patients with newly diagnosed multiple myeloma (MM). The study found that this treatment was well tolerated...Read More
Comparing the outcomes of Retzius-sparing versus standard robotic prostate surgery for the treatment of localized prostate cancer.
In a nutshell This study compared the outcomes of Retzius-sparing (RS) robotic-assisted laparoscopic prostatectomy (RALP) with standard RALP (sRALP) for the treatment of patients with localized prostate cancer (PCa). The study found that the RS-RALP approach may be associated with better urinary outcomes compared to sRALP. Some background...Read More
Can nivolumab plus ipilimumab combined with chemotherapy be used as a first-line treatment for patients with non-small cell lung cancer?
In a nutshell This trial looked at nivolumab (Opdivo) plus ipilimumab (Yervoy) combined with 2 cycles of chemotherapy as treatment for patients with non-small cell lung cancer (NSCLC). The authors found that this combination provided an improved overall survival versus chemotherapy-only regimens. Some background NSCLC is responsible for 85% of...Read More
Evaluating the combination of sipuleucel-T with radium-223 in men with metastatic castration-resistant prostate cancer spread to the bone.
In a nutshell The study investigated the effectiveness of combining sipuleucel-T (Provenge) with radium-223 (Xofigo) therapy in men with castration-resistant prostate cancer (CRPC) that has spread to the bones. The key finding was that the combination therapy improved the survival rates of these patients. Some background Prostate cancer often...Read More
In a nutshell This study tested the safety and effectiveness of pirtobrutinib (LOXO-305) in the treatment of patients with B cell leukemia-lymphoma. The authors found that pirtobrutinib was safe and had promising effectiveness in these patients. Some background B cells are a type of cell of the immune system. Some lymphomas and leukemias such as...Read More
In a nutshell This study tested the safety and effectiveness of pirtobrutinib (LOXO-305) in the treatment of patients with B cell leukemia/lymphoma. The authors found that pirtobrutinib was safe and had promising effectiveness in these patients. Some background B cells are a type of cell of the immune system. Some lymphomas and leukemias such as...Read More
In a nutshell This study aimed to investigate if combined CD19 and CD22 chimeric antigen receptor (CAR) T-cell therapies could be used to treat patients with relapsed acute lymphoblastic leukemia (ALL) after transplant. This study concluded that this combination improved long-term survival for these patients. Some...Read More
In a nutshell This study looked at the use of colchicine (Colcrys) in the treatment of coronary artery disease (CAD). It found that patients treated with colchicine had a lower risk of heart attack, stroke, or heart disease-related death. Some background CAD is a disease in which the blood vessels in the heart become blocked. It can...Read More
In a nutshell This study compared the risk of hypoglycemia (dangerously low blood glucose levels) for insulin glargine 300 U/ml (Gla-300; Toujeo) and standard-of-care basal insulin (SOC-BI) at patients with type 2 diabetes (T2D) with risk factors for hypoglycemia. It found that Gla-300 was associated with a lower risk of hypoglycemia than...Read More
In a nutshell This study looked at the effectiveness of durvalumab (Imfinzi) with or without tremelimumab plus platinum-etoposide (Etopophos) (PE) versus PE-alone for the treatment of extensive-stage small-cell lung cancer (ESCLC). The authors found that durvalumab plus PE showed sustain survival improvement in these patients. Some background...Read More